Aberrant Platelet Mechanisms in Inherited Human Platelet Function Disorders

遗传性人类血小板功能障碍中的异常血小板机制

• 批准号: 7482279
• 负责人: Angara Koneti Rao
• 金额: $ 38.03万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-08 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7482279
• 关键词: Address; Agonist; Antiplatelet Drugs; Bernard-Soulier Syndrome; Biochemical; Blood Platelet Disorders; Blood Platelets; Cardiovascular Diseases; Child; Clinical; Complex; Core-Binding Factor; Cytoplasmic Granules; Defect; Disease; District of Columbia; Family member; Foundations; Functional disorder; GTP-Binding Proteins; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Genes; Genetic; Genetic Medicine; Genetics and Medicine; Genome; Genomics; Hematology; Hematopoietic; Hemorrhage; Human; Human Genome Project; Individual; Inherited; Isoenzymes; Knowledge; Laboratories; Lead; Mediating; Medical center; Membrane Glycoproteins; Messenger RNA; Microarray Analysis; Molecular; Molecular Biology; Molecular Profiling; Mutation; Myosin ATPase; Myosin Light Chains; Numbers; Pathway interactions; Patients; Pharmacotherapy; Phospholipase C; Phosphorylation; Physiological; Physiology; Platelet Activation; Platelet Storage Pool Deficiency; Protein Kinase C; Proteins; RUNX1 gene; Reporting; Research; Research Personnel; Selection Bias; Shotguns; Signal Transduction; Signal Transduction Pathway; System; Thrombasthenia; Thrombocytopenia; Thrombosis; Validation; base; concept; experience; human disease; insight; mRNA Expression; novel; novel strategies; phospholipase C beta2; platelet protein P47; programs; protein activation; receptor; receptor function; response; synergism; tool; transcription factor

DESCRIPTION (provided by applicant): Despite tremendous advances in our understanding of platelet physiology, the underlying molecular mechanisms remain unknown in the vast majority of patients with inherited defects in platelet function. Mechanisms, such as deficiencies in membrane glycoproteins and the storage pool deficiency, are commonly considered but occur in a small proportion of patients. Most of these patients are characterized by a bleeding disorder, and impaired aggregation and dense granule secretion on platelet activation, and are currently lumped in a loosely defined group called "platelet secretion/activation defects." The molecular mechanisms in these patients are unknown. Several studies suggest that these patients may have abnormalities in the signal transduction mechanisms. We have documented specific defects in platelet phospholipase C-beta2, Gaq and protein kinase C-theta. Newer approaches are required to define the molecular defects in such patients who constitute an untapped reservoir of new information. We have now applied genome-wide platelet expression profiling using the Affymetrix microarrays to demonstrate a unique decrease in expression of myosin light chain 9 (MYL9, 70 fold decrease) and other genes in a patient with an inherited thrombocytopenia, impaired platelet responses (including myosin and pleckstrin phosphorylation and GPIIb-llla activation), and a heterozygous mutation in transcription factor CBFA2 (Core-binding factor A2), thereby providing proof of concept that expression profiling can indeed be applied to obtain new insights in patients with platelet dysfunction. The microarray technology has hitherto not been applied to such patients. In this project, we propose an integrated approach encompassing, a) detailed biochemical and functional studies on platelet mechanisms, b) platelet expression profiling and c) subsequent validation of the aberrant mechanisms using functional, mutational, biochemical and immunological approaches, to delineate the molecular mechanisms in 15 patients with inherited platelet dysfunction. We have extensive experience in all of the involved approaches. This project is a collaborative effort between two laboratories with strong complementary expertise. It represents application of the recent advances in genomics and the Human Genome Project to a group of patients who are frequently encountered but extremely poorly characterized. Our studies will provide a wealth of information on platelet mechanisms and on potential new targets for antithrombotic therapy.

描述（由申请人提供）：尽管我们对血小板生理学的理解取得了巨大进展，但在绝大多数遗传性血小板功能缺陷患者中，潜在的分子机制仍然未知。机制，如膜糖蛋白和存储池缺陷的缺陷，通常被认为是，但发生在一小部分患者。这些患者中的大多数以出血性疾病、血小板活化时的聚集和致密颗粒分泌受损为特征，并且目前被归为被称为“血小板分泌/活化缺陷”的松散定义的组。“这些患者的分子机制尚不清楚。一些研究表明，这些患者可能有异常的信号转导机制。我们已经记录了血小板磷脂酶C-β 2、Gaq和蛋白激酶C-θ的特定缺陷。需要新的方法来确定这些患者的分子缺陷，这些患者构成了尚未开发的新信息库。我们现在已经应用了全基因组的血小板表达谱，使用Affyssin微阵列来证明肌球蛋白轻链9表达的独特减少（MYL 9，70倍降低）和其他基因在患有遗传性血小板减少症、血小板反应受损的患者中的作用（包括肌球蛋白和普列克底物蛋白磷酸化和GPIIb-IIIa激活），以及转录因子CBFA 2中的杂合突变。（核心结合因子A2），从而提供了表达谱确实可以应用于获得血小板功能障碍患者的新见解的概念证明。微阵列技术迄今尚未应用于此类患者。在这个项目中，我们提出了一个综合的方法，包括，a）详细的生化和功能研究的血小板机制，B）血小板表达谱和c）随后验证的异常机制，使用功能，突变，生化和免疫学的方法，描绘的分子机制，在15例遗传性血小板功能障碍。我们在所有相关方法方面都有丰富的经验。该项目是两个具有强大互补专业知识的实验室之间的合作努力。它代表了基因组学和人类基因组计划的最新进展在一组经常遇到但特征极差的患者中的应用。我们的研究将为血小板机制和抗血栓治疗的潜在新靶点提供丰富的信息。